Health Authorities "Lagevrio, 20,000 Doses to be Initially Imported... On-site Supply from the 26th"

Advance Procurement of 20,000 Units
Supply to Infectious Disease Hospitals After Customs Clearance on the 24th

[Image source=Yonhap News]

[Asia Economy Reporter Ki Ha-young]The quarantine authorities announced on the 23rd that they will first import 20,000 doses of the oral COVID-19 treatment 'Lagevrio' (active ingredient Molnupiravir) from the US company Merck and supply it to treatment sites starting from the 26th.

The Korea Disease Control and Prevention Agency explained regarding the import schedule of Lagevrio, "We have pre-imported 20,000 doses domestically so that Korea MSD can supply it immediately after the Ministry of Food and Drug Safety grants emergency use authorization."

Lagevrio is expected to go through customs clearance on the 24th and be supplied to treatment sites such as infectious disease specialized hospitals starting from the 26th.

On the same day, the Ministry of Food and Drug Safety decided to grant emergency use authorization for Lagevrio. This is the second oral COVID-19 treatment to be introduced domestically after Pfizer's Paxlovid.

Previously, Jeon Hae-cheol, the 2nd Deputy Head of the Central Disaster and Safety Countermeasures Headquarters, stated at the Central Disaster and Safety Countermeasures Headquarters meeting on the 21st that there are plans to import 100,000 doses of Lagevrio.

Regarding the additional import plan for Lagevrio, the Korea Disease Control and Prevention Agency stated, "We will announce it through a briefing after consultation."

This content was produced with the assistance of AI translation services.